Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title
25 Apr 2007 Y's Therapeutics Completes Enrollment of Phase II Trial in the U.S. With YSPSL for Prevention of Delayed Graft Function in Renal Transplantation
24 Apr 2007 Micromet Achieves Milestone in BiTE(R) Research Collaboration with MedImmune
24 Apr 2007 KaloBios Licenses Humaneering(TM) Technology to Major Pharmaceutical Company
20 Apr 2007 MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE(R) Molecule
19 Apr 2007 Anti-Cancer Agent Avastin(R), Approved in Japan
19 Apr 2007 Viventia Biotech generates novel human anti-cancer antibody, VB1-050, and identifies its novel target
18 Apr 2007 Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models
18 Apr 2007 Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
18 Apr 2007 Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
17 Apr 2007 YM BioSciences' Partner Daiichi Sankyo Receives Clearance for Initial Clinical Trial in Japan
17 Apr 2007 Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
17 Apr 2007 Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
13 Apr 2007 Genmab Initiates HuMax-EGFr Combination Study in Non Small Cell Lung Cancer
13 Apr 2007 XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
07 Apr 2007 FDA approves Cangene's HepaGam B(TM) for a second indication; for use in hepatitis B-positive liver transplant recipients
05 Apr 2007 Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III Head and Neck Cancer Study
05 Apr 2007 Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III Head and Neck Cancer Study
05 Apr 2007 Genzyme Files for Expanded Label for Campath(R) as First-Line Treatment for B-CLL Patients
05 Apr 2007 Crucell Announces Start of Rabies Phase I Antibody Cocktail Clinical Study in India four months after launching initial US Trial
05 Apr 2007 AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody
05 Apr 2007 Cerimon Pharmaceuticals Initiates ARREST UC-1, a Global Phase 2b Study of Basiliximab in Patients with Steroid-Refractory Ulcerative Colitis
04 Apr 2007 WILEX gives positive update of current pivotal Phase III trial of RENCAREX(R)
04 Apr 2007 Viventia Biotech initiates patient treatment for Vicinium(TM) Phase II bladder cancer trial
04 Apr 2007 Pharmexa and Affitech enter into an exclusive license agreement to promote Diabody technology
03 Apr 2007 Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
31 Mar 2007 Astellas Licenses Regeneron Velocimmune(R) Technology For Discovering Human Monoclonal Antibodies
30 Mar 2007 NEOPHARM Reports on FDA Meeting
30 Mar 2007 Anthrax Monoclonal Antibody Valortim(TM) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection
30 Mar 2007 XTL Announces the Completion of Phase I Study with XTL-6865 in Patients with Chronic Hepatitis C
29 Mar 2007 Avastin Approved in Europe for First Line Treatment of Women with Metastatic Breast Cance
29 Mar 2007 MorphoSys and Astellas Enter Antibody Partnership - Deal Seals MorphoSys's Third Japanese Pharmaceutical Alliance
28 Mar 2007 Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
28 Mar 2007 Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
27 Mar 2007 Herceptin receives positive opinion in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2- and hormone receptor-positive metastatic breast cancer
27 Mar 2007 European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
24 Mar 2007 MedImmune Expands Anti-Interferon-Alpha Program by Initiating Phase 1 Trial in Patients With Psoriasis
24 Mar 2007 UCB Provides Update on Cimzia for Crohn's Disease and Rheumatoid Arthritis in the US
23 Mar 2007 Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's ONCONASE(R)
23 Mar 2007 MilleGen and LFB Sign Research Partnership Agreement to Develop New Generation of Therapeutic Monoclonal Antibodies
23 Mar 2007 Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial Evaluating Vectibix(TM) As Part Of Triple Combination Regimen
22 Mar 2007 Peregrine Pharmaceuticals Completes Patient Enrollment in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
22 Mar 2007 Phase II/III pivotal study with trifunctional antibody removab(R) shows encouraging results in malignant ascites from various cancers
22 Mar 2007 Emergent BioSolutions Files Investigational New Drug Application With FDA for Pivotal Anthrax Immune Globulin Clinical Trial
21 Mar 2007 Pain Therapeutics Cleared to Initiate Phase I Study in Metastatic Melanoma
17 Mar 2007 FDA Approves Alexion's Soliris(TM) for All Patients With PNH
17 Mar 2007 Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
17 Mar 2007 Genmab in Research Cooperation with the Dahanca-Group
13 Mar 2007 Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
13 Mar 2007 Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation
13 Mar 2007 TopoTarget Executes Its Licensing Option for the Development of Zemab for Breast Cancer
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
Results 651 - 700 of 1155

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics